CARIS LIFE SCIENCES INC (CAI) Stock Price, Forecast & Analysis
NASDAQ:CAI • US1421521071
CAI Key Statistics, Chart & Performance
The current stock price of CAI is 20.62 USD. In the past month the price decreased by -23.97%.
CAI Technical Analysis
CAI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CAI. While CAI seems to be doing ok healthwise, there are quite some concerns on its profitability.
CAI Financial Highlights
Over the last trailing twelve months CAI reported a non-GAAP Earnings per Share(EPS) of -3.58. The EPS increased by 18.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -101.38% | ||
| ROE | -208.66% | ||
| Debt/Equity | 0.79 |
CAI Forecast & Estimates
13 analysts have analysed CAI and the average price target is 38.65 USD. This implies a price increase of 87.42% is expected in the next year compared to the current price of 20.62.
For the next year, analysts expect an EPS growth of -131.19% and a revenue growth 80.21% for CAI
CAI Ownership
CAI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CAI
Company Profile
Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. The company is headquartered in Irving, Texas. The company went IPO on 2025-06-18. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Company Info
CARIS LIFE SCIENCES INC
750 W. John Carpenter Freeway, Suite 800
Irving TEXAS 94105 US
CEO: Timothy B. Page
Employees: 0
Phone: 18667718946
CARIS LIFE SCIENCES INC / CAI FAQ
What does CAI do?
Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. The company is headquartered in Irving, Texas. The company went IPO on 2025-06-18. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Can you provide the latest stock price for CARIS LIFE SCIENCES INC?
The current stock price of CAI is 20.62 USD. The price decreased by -0.15% in the last trading session.
What is the dividend status of CARIS LIFE SCIENCES INC?
CAI does not pay a dividend.
What is the ChartMill technical and fundamental rating of CAI stock?
CAI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is CAI stock listed?
CAI stock is listed on the Nasdaq exchange.
What is the analyst forecast for CAI stock?
13 analysts have analysed CAI and the average price target is 38.65 USD. This implies a price increase of 87.42% is expected in the next year compared to the current price of 20.62.
What is the GICS sector and industry of CAI stock?
CARIS LIFE SCIENCES INC (CAI) operates in the Health Care sector and the Biotechnology industry.